四川科伦药业股份有限公司（以下简称"公司"）近日获悉，公司控股子公司四川科伦博泰生物医药股份 有限公司（以下简称"科伦博泰"）与Crescent Biopharma, Inc.及其全资子公司Crescent Biopharma Operating Company, LLC (以下合称"Crescent"或"Crescent Biopharma")已建立战略合作伙伴关系，共同开 发和商业化肿瘤治疗手段（包括新型联用疗法）。 一、合作基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002422 证券简称：科伦药业 公告编号：2025-083 四川科伦药业股份有限公司 关于子公司与Crescent Biopharma合作业务进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 CR-001(亦称SKB118) CR-001是一款四价双抗，目前正开发用于治疗实体瘤。其结合了肿瘤学中两种互补且经过验证的作用 机制一一PD-1和VEGF阻断，其中对PD-1检查点的抑制可恢复T细胞识别和摧毁肿瘤细胞的能力，而 VEGF阻断可减少对肿瘤细胞的血液供 ...

Core Viewpoint - The National Medical Products Administration announced that 35 batches of drugs produced by 29 companies do not meet regulatory standards, including two batches of sodium bicarbonate injection from Sichuan Kelun Pharmaceutical Co., Ltd. [1] Group 1: Regulatory Issues - The two batches of sodium bicarbonate injection from Sichuan Kelun Pharmaceutical were found non-compliant regarding pH value, insoluble particles, and visible foreign matter [1][2] - The inspection was conducted by the Anhui Food and Drug Inspection Institute [1][2] Group 2: Company Performance - In the first three quarters of the year, Kelun Pharmaceutical reported total revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% [3] - The company has experienced a continuous decline in net profit for four consecutive quarters [3][4] - In November, Kelun Pharmaceutical received a registration notice for a short-term financing bond with a registration limit of 4 billion yuan, valid for two years [3] Group 3: Market Data - As of December 4, Kelun Pharmaceutical's stock closed at 34.10 yuan per share, with a total market capitalization of 54.494 billion yuan [3][5] - The stock has seen a price increase of 0.29% on that day [5]

公告显示，此次合作涉及科伦博泰一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为载荷的抗体偶联 药物(ADC) SKB105，以及Crescent一款程序性细胞死亡-1(PD-1)×血管内皮生长因子(VEGF)双特异性抗 体CR-001。这两款候选药物均正在开发用于治疗实体瘤，预计于2026年第一季度开展1/2期单药治疗临 床试验。 基于此次合作，科伦博泰将向Crescent收取8000万美元的首付款，并有资格收取高达12.5亿美元的里程 碑付款，以及基于SKB105净销售额的中个位数至低双位数百分比的分级特许权使用费。Crescent将向科 伦博泰收取2000万美元的首付款，并有资格收取高达3000万美元的里程碑付款，以及基于CR-001净销 售额的低至中个位数百分比的分级特许权使用费。 北京商报讯（记者 丁宁）12月4日晚间，科伦药业（002422）发布公告称，公司近日获悉，公司控股子 公司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）与Crescent Biopharma, Inc.及其全资 子公司Crescent Biopharma Operating Company, LLC(以下合称 ...

Core Viewpoint - The strategic partnership between Sichuan Kelun Biotech Co., Ltd. and Crescent Biopharma aims to develop and commercialize innovative cancer therapies, including new combination treatments [1][2]. Group 1: Partnership Details - The collaboration involves Kelun Biotech's SKB105, an antibody-drug conjugate targeting integrin β6, and Crescent's dual-specific antibody CR-001, which targets PD-1 and VEGF, both intended for solid tumor treatment [2]. - The partnership grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105 outside of Greater China, while Kelun Biotech receives exclusive rights for CR-001 within Greater China [2]. Group 2: Financial Aspects - Kelun Biotech will receive an upfront payment of $80 million from Crescent, with potential milestone payments up to $1.25 billion and tiered royalties based on SKB105's net sales [3]. - Crescent will pay Kelun Biotech an upfront fee of $20 million, with milestone payments up to $30 million and tiered royalties based on CR-001's net sales [3]. Group 3: Strategic Implications - This collaboration enhances Kelun Biotech's differentiated oncology pipeline and accelerates the global development of SKB105, increasing its commercial potential and expanding the company's global partnership network [3]. - The partnership leverages both companies' resources to explore new monotherapy and combination therapy strategies in cancer treatment, maximizing the therapeutic potential of both candidates in China and globally [3].

Core Insights - The company, Kelun Pharmaceutical, has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize oncology treatment methods [1] Group 1: Partnership Details - The collaboration involves two candidate drugs: Kelun's SKB105 and Crescent's CR-001 [1] - Kelun grants Crescent exclusive rights to develop SKB105 in markets outside the US, Europe, and Greater China, while Crescent grants Kelun exclusive rights to develop CR-001 in Greater China [1] Group 2: Financial Aspects - Kelun will receive an upfront payment of $80 million from Crescent and has the potential to earn up to $1.25 billion in milestone payments [1] Group 3: Strategic Implications - This partnership allows Kelun to enhance and diversify its oncology research pipeline by incorporating CR-001 [1]

Core Insights - The company announced a strategic partnership with Crescent Biopharma to jointly develop and commercialize oncology treatments [1] - The collaboration involves two candidate drugs: SKB105 from the company and CR-001 from Crescent [1] - The company grants Crescent exclusive rights to develop SKB105 outside the US, Europe, and Greater China, while Crescent grants the company exclusive rights to develop CR-001 in Greater China [1] Financial Aspects - The company will receive an upfront payment of $80 million from Crescent [1] - There is potential for the company to earn up to $1.25 billion in milestone payments [1] Research and Development - The partnership includes the development of both monotherapy and combination therapy for the two candidate drugs [1] - The collaboration enhances the company's differentiated oncology research pipeline by incorporating CR-001 [1]

此次合作涉及科伦博泰一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为载荷的抗体偶联药物 (ADC)SKB105，以及Crescent一款程序性细胞死亡-1(PD-1)×血管内皮生长因子(VEGF)双特异性抗体CR- 001。这两款候选药物均正在开发用于治疗实体瘤，预计于2026年第一季度开展1/2期单药治疗临床试 验。 人民财讯12月4日电，科伦药业（002422）12月4日公告，公司控股子公司科伦博泰与Crescent Biopharma,Inc.及其全资子公司(合称"Crescent"或"Crescent Biopharma")已建立战略合作伙伴关系，共同 开发和商业化肿瘤治疗手段(包括新型联用疗法)。 ...

Core Viewpoint - The company has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, which includes significant financial arrangements and potential future earnings from sales royalties [1] Financial Arrangements - Sichuan Kelun Botai Biopharmaceutical Co., Ltd. will receive an upfront payment of $80 million from Crescent Biopharma [1] - The company is eligible for up to $1.25 billion in milestone payments based on the partnership's success [1] - Additionally, Kelun Botai will receive tiered royalties ranging from mid-single to low-double digits percentage based on the net sales of SKB105 [1] Additional Financial Terms - Crescent Biopharma will pay an upfront fee of $20 million to Kelun Botai and is eligible for up to $30 million in milestone payments [1] - Crescent will also pay tiered royalties based on the net sales of CR-001, starting from low to mid-single digits percentage [1] Control Change Provisions - If there is a change in control at Crescent or if they enter into sublicensing agreements with third parties, Kelun Botai may receive additional payments [1]

一、合作基本情况 此次合作涉及科伦博泰一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为 载荷的抗体偶联药物(ADC) SKB105，以及 Crescent 一款程序性细胞死亡-1(PD-1) ×血管内皮生长因子(VEGF)双特异性抗体(以下简称"双抗") CR-001。这两款 候选药物均正在开发用于治疗实体瘤，预计于 2026 年第一季度开展 1/2 期单药 治疗临床试验。 根据合作条款，科伦博泰授予 Crescent 在美国、欧洲及所有其他大中华地区 （包括中国大陆、香港、澳门及台湾）以外市场研究、开发、生产和商业化 SKB105 的独家权利。Crescent 则授予科伦博泰在大中华地区研究、开发、生产和商业化 CR-001 的独家权利。此次合作包括开发两款候选药物的单药疗法，以及评估 CR-001 与 SKB105 的联用疗法。科伦博泰及 Crescent 均有权独立开发 CR-001 的其他联用方案，包括 CR-001 与各自专有的 ADC 管线资产联用。 基于此次合作，科伦博泰将向 Crescent 收取 8,000 万美元的首付款，并有资 格收取高达 12.5 亿美元的里程碑付款，以及基于 S ...

Core Viewpoint - Kolon Pharmaceutical's subsidiary, Kolon Biotech, has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, focusing on two drugs for solid tumors [1] Group 1: Partnership Details - The collaboration involves Kolon Biotech's SKB105 and Crescent's CR-001, both aimed at treating solid tumors [1] - Kolon Biotech grants Crescent exclusive rights in markets outside Greater China, while Crescent grants Kolon Biotech exclusive rights in Greater China [1] Group 2: Financial Terms - Kolon Biotech will receive an upfront payment of $80 million, along with up to $1.25 billion in milestone payments and royalties based on sales [1] - Crescent will receive an upfront payment of $20 million, with potential milestone payments of up to $30 million and royalties based on sales [1]